What is the 13F Pro Quality Score for CATX?

13F Pro ranks Perspective Therapeutics, Inc. (CATX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CATX's current score at https://13fpro.ai/research/CATX (free sign-up required for the full ranking).

Where does 13F Pro source CATX data?

All Perspective Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Perspective Therapeutics, Inc. files with the SEC under CIK 728387. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CATX in?

Perspective Therapeutics, Inc. (CATX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CATX research updated on 13F Pro?

CATX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Perspective Therapeutics, Inc.(CATX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 728387 CATX stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

CATX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Perspective Therapeutics, Inc. (CATX), a Healthcare sector company. CATX is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q3 2026), Perspective Therapeutics, Inc. reports net income of $-26.2M, free cash flow of $-38.3M. Top institutional holders of CATX by reported 13-F value include TCG Crossover Management,, Commodore Capital, Avidity Partners Management, based on the most recent SEC filings. CATX trades on the NYSE exchange and files with the SEC under CIK 728387. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CATX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Perspective Therapeutics, Inc. directly from SEC EDGAR.

Net Income

Q3 2026

$-26.2M

Free Cash Flow

Q3 2026

$-38.3M

D/E Ratio

Q3 2026

0.00

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+23.5% YoY

$7.3MFY 2019

FY16 $4.8MFY17 $4.8MFY18 $5.9MFY19 $7.3M

Net Income

+23.2% YoY

$-5.1MFY 2019

FY16 $-4.7MFY17 $-6.2MFY18 $-6.7MFY19 $-5.1M

Operating Income

+21.9% YoY

$-5.3MFY 2019

FY16 $-5.1MFY17 $-6.3MFY18 $-6.7MFY19 $-5.3M

Total Assets

+26.4% YoY

$9.4MFY 2019

FY16 $18.1MFY17 $12.3MFY18 $7.5MFY19 $9.4M

Op. Cash Flow

+11.6% YoY

$-5.0MFY 2019

FY16 $-3.9MFY17 $-5.7MFY18 $-5.7MFY19 $-5.0M

Metric	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2013
Revenue	$7.3M +23.5%	$5.9M +24.4%	$4.8M -0.2%	$4.8M +3.5%	$4.6M +1.8%	$4.5M
Net Income	$-5.1M +23.2%	$-6.7M -8.7%	$-6.2M -30.8%	$-4.7M -28.0%	$-3.7M +4.6%	$-3.9M
Operating Income	$-5.3M +21.9%	$-6.7M -6.7%	$-6.3M -24.1%	$-5.1M -17.2%	$-4.3M -6.6%	$-4.1M
Total Assets	$9.4M +26.4%	$7.5M -39.2%	$12.3M -32.2%	$18.1M -21.3%	$23.0M +226.0%	$7.1M
Operating Cash Flow	$-5.0M +11.6%	$-5.7M +0.0%	$-5.7M -47.1%	$-3.9M	—	$-3.1M

AI Insight: CATX Financial Trends

Perspective Therapeutics remains pre-revenue with accelerating operating losses and equity eroding 39% since Q2 2024, partially reversed by Q1 2026 capital raise.

• Operating losses widened from $14M in Q2 2024 to $40M in Q4 2025, reflecting sustained R&D spending with no offsetting revenue.

• Equity declined from $341M to $207M by Q4 2025, then recovered to $347M in Q1 2026, indicating dilutive financing activity.

• Operating cash burn averaged $19M across last four quarters; Q1 2026 saw $31M cash outflow despite capital infusion.

⚠ Cash runway shrinking: at current $25M avg quarterly burn, equity capital covers ~14 quarters without revenue inflection.

⚠ Q4 2025 net loss of $37M — highest on record — signals development acceleration but no near-term commercialization path visible.

AI Insight: CATX Ratio Trends

Perspective Therapeutics remains deeply unprofitable with deteriorating ROIC; Q4 2025 marked a nadir before modest Q1 2026 recovery.

• ROIC collapsed to -76.4% in Q4 2025, worst quarter on record, then partially recovered to -32.4% in Q1 2026.

• ROE and ROA followed identical pattern: Q4 2025 trough at -72.4% and -56.2%, respectively, then improved in Q1 2026.

• Debt-to-equity remained negligible (0.00–0.01) throughout; balance sheet leverage poses no immediate risk.

⚠ Q4 2025 catastrophic loss swing suggests possible one-off charge or operational crisis; Q1 2026 rebound credibility uncertain.

⚠ TTM ROIC of -34.4% reflects four quarters of persistent, large losses; no path to profitability evident in data.

Get alerted when CATX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Perspective Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CATX

TCG Crossover Management, LLC
$33.0M7,915,567 sh
Commodore Capital LP
$26.4M6,336,782 sh
Avidity Partners Management LP
$23.6M6,049,999 sh
BlackRock, Inc.
$22.3M5,348,561 sh
Opaleye Management Inc.
$19.5M4,675,000 sh
VANGUARD CAPITAL MANAGEMENT LLC
$18.3M4,378,956 sh
MILLENNIUM MANAGEMENT LLC
$16.9M4,046,640 sh
CITADEL ADVISORS LLC
$14.9M3,566,504 sh
Affinity Asset Advisors, LLC
$13.2M3,164,582 sh
STATE STREET CORP
$13.1M3,132,670 sh

Fund	Value	Shares
TCG Crossover Management, LLC	$33.0M	7,915,567
Commodore Capital LP	$26.4M	6,336,782
Avidity Partners Management LP	$23.6M	6,049,999
BlackRock, Inc.	$22.3M	5,348,561
Opaleye Management Inc.	$19.5M	4,675,000
VANGUARD CAPITAL MANAGEMENT LLC	$18.3M	4,378,956
MILLENNIUM MANAGEMENT LLC	$16.9M	4,046,640
CITADEL ADVISORS LLC	$14.9M	3,566,504
Affinity Asset Advisors, LLC	$13.2M	3,164,582
STATE STREET CORP	$13.1M	3,132,670

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CATX on your watchlist

Track score changes the day Perspective Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CATX a good stock to buy?

13F Pro's AI-powered analysis of Perspective Therapeutics, Inc. (CATX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CATX are available on the CATX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CATX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CATX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Perspective Therapeutics, Inc.'s investment landscape.